GSK Pharmaceuticals Reports Strong Q2 FY27 Financial and Operational Performance
GlaxoSmithKline Pharmaceuticals Ltd · Intimation · 04 Nov 2026, 6:38 pm
GSK Pharmaceuticals Reports Strong Q2 FY27 Financial and Operational Performance GSK Pharmaceuticals delivered standalone Q2 FY27 revenue of ₹1,180cr (+21% YoY) and H1 revenue of ₹2,104cr (+18% YoY). EBITDA grew 20% YoY to ₹400cr (34% margin, -50 bps YoY), while PAT surged 33% YoY to ₹335cr (29% margin), aided by income tax refund interest; Q2 EPS rose 32% to ₹19.76. Growth was driven by general medicines (Augmentin, Calpol) and doubled Shingrix sales, lifting the innovation portfolio to 7% of revenue versus 3% in prior year. GSK maintained 25% share in its represented market.
Original exchange filing (PDF)
More announcements from GlaxoSmithKline Pharmaceuticals Ltd
- As per attachment · 08 Nov 2026
- As per attachment · 05 Nov 2026
- As per attachment · 05 Nov 2026
- As per attachment · 04 Nov 2026
- As per attachment · 04 Nov 2026
- As per attachment · 04 Nov 2026
- outcome of Meeting · 04 Nov 2026
- GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 04 Nov 2026
